Department of Molecular and Translational Medicine, University of Brescia, Italy.
Department of Ophthalmology, University of Brescia, Italy.
Prog Retin Eye Res. 2019 Sep;72:100756. doi: 10.1016/j.preteyeres.2019.03.002. Epub 2019 Apr 2.
Diabetic retinopathy (DR) is one of the leading causes of visual impairment in the working-age population. DR is a progressive eye disease caused by long-term accumulation of hyperglycaemia-mediated pathological alterations in the retina of diabetic patients. DR begins with asymptomatic retinal abnormalities and may progress to advanced-stage proliferative diabetic retinopathy (PDR), characterized by neovascularization or preretinal/vitreous haemorrhages. The vitreous, a transparent gel that fills the posterior cavity of the eye, plays a vital role in maintaining ocular function. Structural and molecular alterations of the vitreous, observed during DR progression, are consequences of metabolic and functional modifications of the retinal tissue. Thus, vitreal alterations reflect the pathological events occurring at the vitreoretinal interface. These events are caused by hypoxic, oxidative, inflammatory, neurodegenerative, and leukostatic conditions that occur during diabetes. Conversely, PDR vitreous can exert pathological effects on the diabetic retina, resulting in activation of a vicious cycle that contributes to disease progression. In this review, we recapitulate the major pathological features of DR/PDR, and focus on the structural and molecular changes that characterize the vitreal structure and composition during DR and progression to PDR. In PDR, vitreous represents a reservoir of pathological signalling molecules. Therefore, in this review we discuss how studying the biological activity of the vitreous in different in vitro, ex vivo, and in vivo experimental models can provide insights into the pathogenesis of PDR. In addition, the vitreous from PDR patients can represent a novel tool to obtain preclinical experimental evidences for the development and characterization of new therapeutic drug candidates for PDR therapy.
糖尿病视网膜病变(DR)是导致工作年龄人群视力损害的主要原因之一。DR 是一种由糖尿病患者长期高血糖介导的视网膜病理改变积累引起的进行性眼病。DR 始于无症状的视网膜异常,可能进展为晚期增生性糖尿病视网膜病变(PDR),其特征为新生血管形成或视网膜前/玻璃体积血。玻璃体是一种填充眼球后腔的透明凝胶,在维持眼部功能方面起着至关重要的作用。在 DR 进展过程中观察到的玻璃体结构和分子改变是视网膜组织代谢和功能改变的结果。因此,玻璃体改变反映了在玻璃体视网膜界面发生的病理事件。这些事件是由糖尿病发生时缺氧、氧化、炎症、神经退行性和白细胞增多引起的。相反,PDR 玻璃体可以对糖尿病视网膜产生病理影响,导致恶性循环的激活,从而促进疾病的进展。在这篇综述中,我们总结了 DR/PDR 的主要病理特征,并重点介绍了在 DR 和进展为 PDR 过程中表征玻璃体结构和组成的结构和分子变化。在 PDR 中,玻璃体是病理性信号分子的储存库。因此,在这篇综述中,我们讨论了如何研究不同体外、离体和体内实验模型中玻璃体的生物学活性,可以深入了解 PDR 的发病机制。此外,PDR 患者的玻璃体可以作为一种新工具,为 PDR 治疗的新治疗药物候选物的开发和表征提供临床前实验证据。